Abstracts tagged "neuropathy and pain"

Abstract Number: 451 • 2018 ACR/ARHP Annual Meeting
The Frequency of Neuropathic Pain in Patients with Low Back Pain and the Relationship with Demographic Characteristics: A Cross-Sectional Study
Belgin Erhan, Kevser Gumussu, Belgin Kara, Gül Tuğba Bulut and Ebru Yılmaz Yalçınkaya, Physical Medicine and Rehabilitation, GOP Taksim Training and Research Hospital, Gaziosmanpasa, Turkey
Background/Purpose: Low back pain (LBP) is one of the most challenging chronic pain conditions. The pathophysiology of LBP is complex and contains nociceptive and neuropathic…
Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 1443 • 2015 ACR/ARHP Annual Meeting
A Multiple Ascending-Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirogabalin in Healthy Elderly Subjects
Karen Brown¹, Yoshihiro Kumagae¹, Shoichi Ohwada², Vance Warren¹, Hamim Zahir¹ and Victor Dishy¹, ¹Daiichi Sankyo Pharma Development, Edison, NJ, ²Daiichi Sankyo Co., Ltd., Tokyo, Japan
Background/Purpose: Mirogabalin (DS-5565) is a preferentially selective a2d-1 ligand intended for treatment of pain associated with fibromyalgia and neuropathic pain. We evaluated the safety, tolerability,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].